GKOS - NYSE
Glaukos Corporation
$113.64
+2.6%Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
At a Glance
Live SnapshotGlaukos Corporation Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Glaukos Corporation Income Statement
GKOS • NYSE
| Glaukos Corporation Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||
507.4M | 383.5M | 314.7M | 282.9M | 294M | 225M | 237M | 181.3M | 159.3M | 114.4M | 71.7M | 45.6M | 20.9M | 2.4M | |
GROSS PROFIT | ||||||||||||||
(114.2M) | (94M) | (75.6M) | (69M) | (66.6M) | (91.7M) | (38.6M) | (25.1M) | (21.1M) | (16.2M) | (13M) | (11.4M) | (2.5M) | (1.7M) | |
393.2M | 289.5M | 239.1M | 213.9M | 227.4M | 133.2M | 198.4M | 156.2M | 138.2M | 98.2M | 58.7M | 34.2M | 18.4M | 774K | |
OPERATING INCOME | ||||||||||||||
(479.9M) | (411.8M) | (367.8M) | (296.2M) | (260.3M) | (256.8M) | (248.7M) | (169.2M) | (140.5M) | (94M) | (69M) | (47.3M) | (32.6M) | (22.6M) | |
(329.3M) | (262.8M) | (224.1M) | (192.9M) | (179.3M) | (171.4M) | (176.6M) | (119.5M) | (96.3M) | (64.8M) | (44M) | (28.1M) | (17.1M) | (9.6M) | |
(150.6M) | (136.4M) | (138.8M) | (123.3M) | (101M) | (85.4M) | (68.3M) | (49.7M) | (38.9M) | (29.2M) | (25M) | (19.2M) | (15.5M) | (13.3M) | |
-86.7M | -122.4M | -128.7M | -82.3M | -32.9M | -123.6M | -50.3M | -13M | -2.3M | 4.2M | -10.3M | -13.2M | -14.2M | -22.1M | |
PRE-TAX INCOME | ||||||||||||||
(4.6M) | (10M) | (13.6M) | (13.7M) | (13.4M) | (14.1M) | (2.6M) | (0.0) | (0.0) | (608K) | (1.1M) | (876K) | (307K) | (0.0) | |
6.1M | 1.1M | -4.5M | -11.3M | -12.1M | -11.7M | 604K | 2.3M | 1.4M | 281K | -980K | -873K | -294K | 0.0 | |
(0.0) | (12.5M) | (5M) | -20M | -20M | (0.0) | (3.7M) | (0.0) | (5.3M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-106.3M | -23.2M | -5M | -16.1M | -16.4M | -8.8M | 256K | 634K | 2.3M | 324K | -28M | -868K | -23K | 79K | |
-193M | -145.6M | -133.7M | -98.4M | -49.3M | -132.3M | -50M | -12.4M | 1K | 4.6M | -38.3M | -14M | -14.2M | -22M | |
NET INCOME | ||||||||||||||
-5.4M | (771K) | (934K) | (766K) | (326K) | -12M | -65.5M | (583K) | (93K) | (43K) | (33K) | (18K) | (6K) | (3K) | |
-187.7M | -146.4M | -134.7M | -99.2M | -49.6M | -120.3M | 15.4M | -13M | -92K | 4.5M | -37.2M | -12.1M | -12.6M | -19.3M |
SEC Filings
GKOS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 04, 2026 | May 04, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 30, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 16, 2026 | May 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 02, 2026 | March 02, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 23, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 17, 2026 | February 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 13, 2026 | January 13, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 10, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | October 31, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your GKOS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.